GILEAD SCIENCES, INC.
At today's price, GILEAD SCIENCES, INC. (GILD) is priced for +0.8% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
The loudest worry about Gilead is patent risk: Biktarvy alone is $3.36 billion a quarter, and one drug carrying the company invites a cliff fear. The data tempers it. At $123.63 (as of June 27, 2026) the price implies roughly flat operating growth, a low bar, and the company is below the middle of its peer multiple range. The valuation is supported by the relative-multiple and growth-DCF lenses, while asset and earnings-power frames call it expensive. Several methods land above the price, and t
Is GILD overvalued? See what's priced in →
2,256 institutional managers reported holding GILD in 13F filings for the quarter ended 2026-03-31. Together they hold about 82% of the company; the top 10 hold 44%. 207 opened new positions that quarter. Held by Vanguard Group, BlackRock, FMR (Fidelity), among others. On the short side, 23.9M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (2.7 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
GILD has cut its share count 1% over the past five years, spending $6.08B on repurchases. It pays a dividend, and has for 11 years running, raised 10 years straight; the current rate is $3.16 a share annually. Cash returned over the past three years: $10.86B in dividends and $3.94B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at GILD over the trailing three years. Absence is a fact about the company, not a signal. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
GILD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-05 | +4.0% | -5.0% |
| 2023-11-08 | -4.0% | +8.5% |
| 2024-02-24 | -0.2% | -11.1% |
| 2024-05-09 | -2.5% | +8.3% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
GILD's latest 8-K filings: 2026-05-20 (items 1.01, 2.03, 8.01, 9.01); 2026-05-07 (items 2.02, 9.01); 2026-05-04 (items 5.07, 9.01); 2026-04-28 (items 7.01, 8.01, 9.01); 2026-02-23 (items 1.01, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.